When TELA Bio reports third-quarter results after the close on November 10, the numbers themselves may matter less than the plan attached to them. Last quarter the company missed its own revenue target, pulled its full-year outlook, saw its plastic and reconstructive surgery (PRS) business slide sharply and replaced its founding chief executive with turnaround-minded Heather Goetz. This report is the first real look at what the new leadership intends to do, and whether the cash on hand gives it enough time to do it.
Wall Street expects a loss of $0.19 per share, matching the year-ago figure, on revenue of about $18.9 million. That would be down 8.7% from $20.7 million a year earlier and slightly below the $19.3 million posted last quarter, so the Street is modeling outright contraction rather than stabilization. There is an awkward wrinkle here. The company withdrew its prior call for 2026 revenue of at least $86.7 million, yet full-year consensus still sits around $86.8 million. With quarterly sales running in the $19 million range, that number looks stale, and a fresh outlook or even an informal framework from Goetz would likely force estimates lower. A reset is not necessarily bad news if it is credible; the guidance history, which slid from at least 15% growth to at least 8% before disappearing, is precisely why credibility is now the scarce commodity.
PRS is the swing factor. Revenue there fell to $5.5 million from $7.3 million a year ago, with units down 23%, after a dedicated-rep pilot confused the sales organization and was scrapped. Management pointed to the July return of a top implanter as an early sign of repair, but the business remains concentrated in fewer than ten sites. A sequential uptick would support the idea that the damage was self-inflicted and fixable; another decline would suggest something more structural, possibly tied to the competitive bundling by BD that the company is fighting in court. The hernia franchise is the other half of the story. Ovitex hernia units grew 12% and dollars rose 6.6% to $13.3 million, international revenue jumped 26% and LiquiFix grew 39%. Those trends need to hold for the core thesis to survive, and any cooling in Europe would remove one of the few clean bright spots.
Margins and cash deserve close attention. Gross margin improved to 72%, but a tariff refund and lower excess and obsolescence charges helped, so a step back toward the 66% seen in the first quarter would not be shocking. Cash dropped to $30.4 million from $39.5 million in a single quarter while interest expense climbed to $2.1 million. Management promised meaningful cost reductions and described a capital raise as a last resort. The specifics of those cuts, and evidence that quarterly burn is moving well below roughly $9 million, will determine whether that last resort stays theoretical. Commentary on sales rep productivity, which was stretched to a 9 to 12 month ramp, will also show whether cuts touch the commercial engine.
The market has kept punishing the shares. The stock is down 11.2% since the last report against a 2.9% decline in the S&P 500, and at $0.80 it trades below its 200-day average of $0.86 and in the lower part of a $0.60 to $1.50 post-earnings range. Sentiment remains bearish but less uniformly so, at 57.3% bearish compared with unanimous pessimism a quarter ago, hinting that some investors are willing to give the new CEO a hearing.
Ultimately, this report turns on whether Goetz can pair a believable revenue baseline with a cost plan that stretches the runway without starving growth. Stabilizing PRS and a clear path to lower burn would validate the turnaround framing; another PRS decline and vague restructuring details would leave financing risk at the center of the story.